BCM
LRMR icon

BlueCrest Capital Management’s Larimar Therapeutics LRMR Stock Holding History

BlueCrest Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,392
Closed -$195K – 1180
2018
Q3 		$195K Buy
+1,392
New +$169K 0.01% 1281
2018
Q2 		– Sell
-5,725
Closed -$512K – 1682
2018
Q1 		$512K Buy
+5,725
New +$485K 0.02% 762

Other funds holding LRMR

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlueCrest Capital Management's LRMR Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2018, closing a stake of 1,392 shares — an estimated $195K sold.

BlueCrest Capital Management first reported a position in LRMR in Q1 2018 and held it in 2 quarters. The position peaked at $512K in Q1 2018. 94 funds tracked by Wall St. Rank hold LRMR as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Larimar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,392 Larimar Therapeutics shares in Q4 2018, an estimated $195K.
  • BlueCrest Capital Management first reported a position in Larimar Therapeutics in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Larimar Therapeutics position peaked at $512K in Q1 2018.
  • 94 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.